These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 25591027)

  • 1. Rescheduling of combination hydrocodone products: problems for long-term care practitioners.
    Mattingly Ii TJ
    Consult Pharm; 2015 Jan; 30(1):13-9. PubMed ID: 25591027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schedules of controlled substances: rescheduling of hydrocodone combination products from schedule III to schedule II. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2014 Aug; 79(163):49661-82. PubMed ID: 25167591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physicians' intention to prescribe hydrocodone combination products after rescheduling: A theory of reasoned action approach.
    Fleming ML; Driver L; Sansgiry SS; Abughosh SM; Wanat M; Sawant RV; Ferries E; Reeve K; Todd KH
    Res Social Adm Pharm; 2017; 13(3):503-512. PubMed ID: 27567741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydrocodone rescheduling.
    Wroten D
    J Ark Med Soc; 2014 Nov; 111(6):100. PubMed ID: 25654919
    [No Abstract]   [Full Text] [Related]  

  • 5. The Effect of a Federal Controlled Substance Act Schedule Change on Hydrocodone Combination Products Claims in a Medicaid Population.
    Tran S; Lavitas P; Stevens K; Greenwood BC; Clements K; Alper CJ; Lenz K; Price M; Hydery T; Arnold JL; Takeshita M; Bacon R; Peristere JP; Jeffrey PL
    J Manag Care Spec Pharm; 2017 May; 23(5):532-539. PubMed ID: 28448772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacists' perceptions regarding the impact of hydrocodone rescheduling on prescription volume, workflow management, and patient outcomes.
    Varisco TJ; Ogunsanya ME; Barner JC; Fleming ML
    J Am Pharm Assoc (2003); 2017; 57(2S):S51-S62. PubMed ID: 28292504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug Enforcement Agency 2014 Hydrocodone Rescheduling Rule and Opioid Dispensing after Surgery.
    Neuman MD; Hennessy S; Small DS; Newcomb C; Gaskins L; Brensinger CM; Wijeysundera DN; Bateman BT; Wunsch H
    Anesthesiology; 2020 May; 132(5):1151-1164. PubMed ID: 32101973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Better late than never: time to up-schedule hydrocodone combination products.
    Kolodny A
    Pain Med; 2013 Nov; 14(11):1627-8. PubMed ID: 24238352
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA to propose hydrocodone reclassification.
    J Calif Dent Assoc; 2014 Jan; 42(1):10. PubMed ID: 25080676
    [No Abstract]   [Full Text] [Related]  

  • 10. Decline in opioid prescribing after federal rescheduling of hydrocodone products.
    Raji MA; Kuo YF; Adhikari D; Baillargeon J; Goodwin JS
    Pharmacoepidemiol Drug Saf; 2018 May; 27(5):513-519. PubMed ID: 29271049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rescheduling of hydrocodone combination products.
    Med Lett Drugs Ther; 2014 Oct; 56(1453):101-2. PubMed ID: 25296260
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug Enforcement Administration Rescheduling of Hydrocodone Combination Products Is Associated With Changes in Physician Pain Management Prescribing Preferences.
    Fleming ML; Driver L; Sansgiry SS; Abughosh SM; Wanat MA; Varisco TJ; Pickard T; Reeve K; Todd KH
    J Pain Palliat Care Pharmacother; 2019; 33(1-2):22-31. PubMed ID: 31454279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA committee: More restrictions needed on hydrocodone combination products.
    Kuehn BM
    JAMA; 2013 Mar; 309(9):862. PubMed ID: 23462764
    [No Abstract]   [Full Text] [Related]  

  • 14. DEA reschedules hydrocodone combination products as schedule II.
    J Mich Dent Assoc; 2014 Oct; 96(10):11. PubMed ID: 25647867
    [No Abstract]   [Full Text] [Related]  

  • 15. The downside of upscheduling.
    Gudin J; Lee AJ
    Pain Med; 2013 Nov; 14(11):1628-9. PubMed ID: 24238353
    [No Abstract]   [Full Text] [Related]  

  • 16. Has the rescheduling of hydrocodone changed ED prescribing practices?
    Oehler EC; Day RL; Robinson DB; Brown LH
    Am J Emerg Med; 2016 Dec; 34(12):2388-2391. PubMed ID: 27776785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent developments toward the safer use of opioids, with a focus on hydrocodone.
    Covvey JR
    Res Social Adm Pharm; 2015; 11(6):901-8. PubMed ID: 25769501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA advisers support rescheduling of hydrocodone products.
    Traynor K
    Am J Health Syst Pharm; 2013 Mar; 70(5):383-4. PubMed ID: 23413158
    [No Abstract]   [Full Text] [Related]  

  • 19. Using trajectory models to assess the effect of hydrocodone upscheduling among chronic hydrocodone users.
    Murimi IB; Chang HY; Bicket M; Jones CM; Alexander GC
    Pharmacoepidemiol Drug Saf; 2019 Jan; 28(1):70-79. PubMed ID: 30187574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Schedules of controlled substances: rescheduling of buprenorphine from schedule V to schedule III. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2002 Oct; 67(194):62354-70. PubMed ID: 12369590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.